Rentosertib is designed to treat IPF by targeting Traf2- and NCK-interacting kinase (TNIK), a serine/threonine kinase whose activation plays a crucial role in cellular processes that include signal ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

ALX Oncology Holdings Inc.’s ALXO share price has dipped by 15.70%, which has investors questioning if this is right time to buy.

Other studies of the CD47-directed antibody in large B cell lymphoma, multiple myeloma and solid tumours are not affected as they don't include azacitidine as a study drug. "While no clear trend ...

Story March 5 - ALX Oncology: As the biotech looks to channel its cash into further trials of its CD47 blocker, the company will lay off 30% of its workforce. Story March 5 - Bristol Myers Squibb ...

It is part of a ‘don’t eat me’ signalling pathway that is governed by the interaction of SIRP-alpha and CD47, another big research area in cancer immunotherapy. It is thought that blockade ...

BERKELEY, CA, USA I March 11, 2025 I Nosis Biosciences, an AI-driven biotechnology company specializing in RNA therapeutics for challenging cell types, today ...

After hours: March 10 at 6:10:27 PM EDT Loading Chart for ADAG ...

As of 2:12:27 PM EDT. Market Open. Loading Chart for ALXO ...

Pre-Market: 5:00:17 a.m. EDT Loading Chart for TGTX ...